ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
-13.4%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$85.2M
AUM Growth
+$85.2M
(+3.2%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-28.53%
Top 10 Holdings %
Top 10 Hldgs %
80.3%
Holding
25
New
8
Increased
5
Reduced
3
Closed
6
Top Buys
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$9.12M |
| 2 |
Axsome Therapeutics
AXSM
|
$7.73M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$6.92M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$5.23M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$4.99M |
Top Sells
| 1 |
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
|
$34.7M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$10.8M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$10.3M |
| 4 |
Viridian Therapeutics
VRDN
|
$4.8M |
| 5 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
$4.24M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $10.4M | 12.25% | 183,105 +91,692 | +100% | +$5.23M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $9.12M | 10.7% | 266,961 | – | – |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.12M | 10.7% | +175,000 | New | +$9.12M |
|
|
4
Axsome Therapeutics
AXSM
$6.05B
| $7.73M | 9.07% | +110,600 | New | +$7.73M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $6.92M | 8.12% | +181,805 | New | +$6.92M |
|
6
Cytokinetics
CYTK
$4.23B
| $6.58M | 7.72% | 223,382 | – | – |
|
7
Merus
MRUS
$4.98B
| $5.22M | 6.13% | 221,384 +22,163 | +11% | +$523K |
|
|
8
Amylyx Pharmaceuticals
AMLX
$836M
| $4.99M | 5.86% | +272,690 | New | +$4.99M |
|
9
Geron
GERN
$893M
| $4.71M | 5.53% | 2,221,639 +98,477 | +5% | +$209K |
|
10
Ardelyx
ARDX
$1.53B
| $3.6M | 4.22% | +881,356 | New | +$3.6M |
|
|
AMAM
11
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $3.23M | 3.79% | +281,089 | New | +$3.23M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.06M | 3.59% | +70,283 | New | +$3.06M |
|
13
Jasper Therapeutics
JSPR
$45.5M
| $2.2M | 2.58% | 3,144,164 +626,932 | +25% | +$439K |
|
14
Black Diamond Therapeutics
BDTX
$157M
| $1.82M | 2.14% | 634,191 -165,809 | -21% | -$476K |
|
15
Praxis Precision Medicines
PRAX
$958M
| $1.81M | 2.12% | 1,056,370 -2,143,630 | -67% | -$3.67M |
|
16
Compass Therapeutics
CMPX
$483M
| $1.8M | 2.11% | 914,630 | – | – |
|
17
Context Therapeutics
CNTX
$75.4M
| $1.1M | 1.29% | 725,951 +72,555 | +11% | +$110K |
|
18
ProMIS Neurosciences
PMN
$28M
| $1.05M | 1.24% | +531,915 | New | +$1.05M |
|
|
MDVL
19
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $707K | 0.83% | 117,897 -5,777,000 | -98% | -$34.7M |
|
20
MDxHealth
MDXH
$176M
| – | – | -349,552 | Closed | -$1.19M |
|
21
Rapid Micro Biosystems
RPID
$107M
| – | – | -403,284 | Closed | -$403K |
|
|
22
Viridian Therapeutics
VRDN
$1.5B
| – | – | -201,752 | Closed | -$4.8M |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| – | – | -487,631 | Closed | -$10.3M |
|
|
MRNS
24
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – | -390,418 | Closed | -$4.24M |
|
|
RETA
25
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – | -105,558 | Closed | -$10.8M |
|